scholarly journals Association Between Ibuprofen Exposure and Severe COVID-19 Infection: A Nationwide Register-Based Study

2020 ◽  
Author(s):  
Kristian Kragholm ◽  
Thomas A. Gerds ◽  
Emil Fosbøl ◽  
Mikkel Porsborg Andersen ◽  
Matthew Phelps ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Odds Ratio ◽  
Virus Disease ◽  
World Health ◽  
Administrative Databases ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
The World ◽  
Health Organization

Abstract Background: Initially, the World Health Organization (WHO) and national health boards issued a warning against NSAID use in corona virus disease 2019 (COVID-19) patients and recommended that paracetamol or acetaminophen instead should be administered. However, later and current WHO and European Medicine Agency recommendations do not call for avoidance of ibuprofen in COVID-19 patients. Given the current uncertainty of drug safety for NSAID use in patients with COVID-19, we performed a nationwide register-based study on the association of recent ibuprofen exposure and COVID-19 severity. Methods: Using national administrative databases, we identified COVID-19 patients in Denmark between end of February 2020 and April 2, 2020. Patients <30 years of age and heart failure, for whom ibuprofen is not recommended, were excluded. Ibuprofen exposure was defined using the Danish National Prescription Registry, where we had information until January 31, 2020. Endpoint was a composite of severe COVID-19 diagnosis with acute respiratory syndrome, intensive care unit admission or death. Results: Among 1,872 patients, 46 (2.5%) were exposed to ibuprofen prior to COVID-19 infection. Patients with recent ibuprofen exposure tended to be older and more likely to have hypertension, diabetes, myocardial infarction, chronic obstructive pulmonary disease, and cancer, though all insignificant (P>0.05). When adjusting for these covariates, odds ratio was 1.57 [95% CI 0.72-3.38], with 12 ibuprofen-exposed patients meeting the endpoint (26.1% [95% CI 13.4-38.8%]) versus 272 unexposed patients (14.9% [95% CI 13.4-16.4%]), P=0.15. Conclusion: The association between ibuprofen and severe COVID-19 was insignificant, although with a trend towards increased disease severity risk.

scholarly journals Association between ibuprofen exposure and severe COVID-19 infection: a nationwide register-based study

2020 ◽  
Author(s):  
Kristian Kragholm ◽  
Thomas A. Gerds ◽  
Emil Fosbøl ◽  
Mikkel Porsborg Andersen ◽  
Matthew Phelps ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Odds Ratio ◽  
Virus Disease ◽  
World Health ◽  
Administrative Databases ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
The World ◽  
Health Organization

Abstract Background: Initially, the World Health Organization (WHO) and national health boards issued a warning against NSAID use in corona virus disease 2019 (COVID-19) patients and recommended that paracetamol or acetaminophen instead should be administered. However, later and current WHO and European Medicine Agency recommendations do not call for avoidance of ibuprofen in COVID-19 patients. Given the current uncertainty of drug safety for NSAID use in patients with COVID-19, we performed a nationwide register-based study on the association of recent ibuprofen exposure and COVID-19 severity.Methods: Using national administrative databases, we identified COVID-19 patients in Denmark between end of February 2020 and April 2, 2020. Patients <30 years of age and heart failure, for whom ibuprofen is not recommended, were excluded. Ibuprofen exposure was defined using the Danish National Prescription Registry, where we had information until January 31, 2020. Endpoint was a composite of severe COVID-19 diagnosis with acute respiratory syndrome, intensive care unit admission or death. Results: Among 1,872 patients, 46 (2.5%) were exposed to ibuprofen prior to COVID-19 infection. Patients with recent ibuprofen exposure tended to be older and more likely to have hypertension, diabetes, myocardial infarction, chronic obstructive pulmonary disease, and cancer, though all insignificant (P>0.05). When adjusting for these covariates, odds ratio was 1.57 [95% CI 0.72-3.38], with 12 ibuprofen-exposed patients meeting the endpoint (26.1% [95% CI 13.4-38.8%]) versus 272 unexposed patients (14.9% [95% CI 13.4-16.4%]), P=0.15. Conclusion: The association between ibuprofen and severe COVID-19 was insignificant, although with a trend towards increased disease severity risk.

Communication and Education Processes Involved in COPD Patient Engagement within the Italian Health System

2017 ◽  
pp. 29-65
Author(s):  
Virginia Recchia ◽  
Antonio Dodaro ◽  
Rosita B. Maglie ◽  
Carlo G. Leo
Keyword(s):  
Health System ◽  
Patient Engagement ◽  
World Health ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Common Cause ◽  
The World ◽  
Advance Care ◽  
Health Organization ◽  
Problem Patient

The World Health Organization has estimated that chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death worldwide. Due to the economic and social extent of the problem, patient engagement must be comprised as a new resource for the achievement of higher health outcomes and lower costs. As many key processes involved in the COPD patient engagement consist of communication and education processes, modelling those processes in a whole framework, including actors and content needs, is a requirement. The main scope of this chapter is contributing to design such a framework within the Italian Health System. Final recommendations suggest to create a synergy among patient engagement and a set of legal tools, namely informed consent, integrated care and advance care planning. The synergy is based on the fact that both patient engagement and those legal tools have a common deep root in the universal principle of patient autonomy.

Prognostic role of transferrin saturation in heart failure patients

2021 ◽  
Author(s):  
Jeness Campodonico ◽  
Flavia Nicoli ◽  
Irene Motta ◽  
Margherita Migone De Amicis ◽  
Alice Bonomi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Transferrin Saturation ◽  
Heart Association ◽  
World Health ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Inflammatory Status ◽  
Group A ◽  
Health Organization ◽  
Worse Prognosis

Abstract Aims In heart failure (HF) iron deficiency (ID) is frequently observed and represents a major mortality risk factor. Purpose of this study was to evaluate the correlation between mortality and ID in a cohort of 661 consecutive patients hospitalized for HF worsening. Methods and results Patients were grouped: (i)according to presence(+)/absence(−) of anaemia (A) and ID defined following World Health Organization (WHO) and European Society of Cardiology (ESC)–American College of Cardiology/American Heart Association/HF society of America (ACC/AHA/HFSA) definitions, respectively: Group A−ID− (n = 123), Group A+ID− (n = 80), Group A+ID+ (n = 247), and Group A−ID+ (n = 211); (ii) according to presence of absolute (serum ferritin &lt; 100μg/L) and functional ID [ferritin between 100 and 300μg/L and transferrin saturation (TSAT) &lt; 20%]; and (iii) according to TSAT &lt;20% and ≥20%. Groups were not different for several clinical features but age, gender, kidney function, and chronic obstructive pulmonary disease. Average follow-up was 1.94 year (±420 days). Overall 5 years mortality rate was 29.5%. Only anaemia and functional ID but not ID as defined by guidelines showed an impact on prognosis. Transferrin saturation &lt;20% (n = 360) patients showed worst prognosis compared to TSAT ≥20% (n = 301) patients. In addition, functional ID patients showed worse prognosis compared patients with ferritin &lt;100μg/L and TSAT &lt;20% or ≥20% likely due to more severe chronic inflammatory status [C-reactive protein, 7.4 (interquartile range 2.7–22.6) and 3.2 (1.4–8.7) mg/L, P &lt; 0.0001 respectively]. Conclusion We confirmed that in HF anaemia is associated to a poor prognosis. Moreover, we showed that patients with TSAT &lt;20% had worse prognosis compared to those with TSAT ≥20% but the composite of ferritin between 100 and 300 μg/L and TSAT &lt;20% identifies HF patients with the poorest survival rate.

scholarly journals DIAGNOSTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN REAL CLINICAL PRACTICE: HYPODIAGNISTICS OR HYPERDIAGNOSTICS

2017 ◽  
Vol 3 ◽  
pp. 65-72
Author(s):  
Nataliya Cherepii ◽  
Lesia Rasputina
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
World Health ◽  
Medical Documentation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Continuous Growth ◽  
The World ◽  
Health Organization ◽  
Severity Degree

According to the data of the world statistics there is observed the continuous growth of chronic obstructive pulmonary disease (COPD). According to the last data of the World health organization (WHO), for today there is near 250 mln persons with chronic obstructive pulmonary disease (COPD), and this disease becomes as cause of death of near 3 mln persons annually. Aim: to establish the prevalence of undiagnosed chronic pulmonary disease (COPD) among persons, who consider themselves as healthy ones and regularly undergo medical check-ups; to estimate the frequency of chronic obstructive pulmonary disease (COPD) according to the data of medical documentation. Methods and materials: 525 persons, older than 35, who did not have in an anamnesis any chronic diseases of respiratory tract, were interrogated. At the following stage, persons, who had taken 18 points or more underwent a spirography with bronchodilatation test, using 400 mcg of salbutamol and were interrogated by the modified questionnaire of short breath by the medical research council (MRC) and test of the chronic obstructive pulmonary disease estimation (COPD) (TEC). There were examined 136 patients, mean age (51,5±0,8), men were 81(59,5 %) mean age (52,2±1,1) and women – 55(40,4 %) mean age (50,7±0,9). There were analyzed 56 medical stories of patients, treated at therapeutic departments of the city clinic because of internal organs diseases with the concomitant diagnosis of chronic obstructive pulmonary disease (COPD). Among persons with first revealed chronic obstructive pulmonary disease у 21 (26,6 %) was reveled І severity degree according to GOLD, in 26 persons (32,9 %) – GOLD ІІ, in 28 (35,4 %) – GOLD ІІІ, in 4 (5,1 %) – GOLD ІV severity degree, so 32 patients did not receive basic treatment at all. At the same time among patients with COPD diagnosis in medical documentation only in 38,4 % this diagnosis was spirographically verified, the hyperdiagnostics of disease on the base of complaints and age characteristic took place in other cases.

scholarly journals Corticosteroid therapy in patients with severe COVID-19

2021 ◽  
Vol 10 (1) ◽  
pp. e58910112114
Author(s):  
Thiago Costa de Araújo Dantas ◽  
Andriny Cunha Apoliano Gomes ◽  
Ikaro Peixoto Correia Lima ◽  
Beatriz Bispo Lucas ◽  
Mateus Rodrigues de Aguiar ◽  
...  
Keyword(s):  
Severe Form ◽  
World Health ◽  
Chronic Obstructive ◽  
Cross Sectional ◽  
Obstructive Pulmonary Disease ◽  
The World ◽  
Proven Efficacy ◽  
Health Organization ◽  
Positive Results ◽  
Term Management

The world panorama of disseminating the new coronavirus SARS-CoV-2 is considered a pandemic by the World Health Organization (WHO) with the risk of complications due to the imbalance of immune responses. The present study evaluated whether the use of corticosteroids has scientifically proven efficacy in treating patients with the severe form of COVID-19. It was a cross-sectional and integrative literature review from December 2019 to November 2020 after researching the PubMed, Scopus, Embase, Web of Science, and Google Scholar databases. According to the studies analyzed, positive results of corticotherapy were observed in patients with SARS-CoV-2 in the severe form of the disease. It was concluded that steroids are not indicated in the mild form of COVID-19 unless they have other comorbidities, such as chronic obstructive pulmonary disease (COPD) or asthma. Glucocorticoid therapy is relevant in the severe form of SARS-CoV-2, with short-term management and low doses being beneficial. It reduces morbidity and mortality and the length of stay in the ICU.

Communication and Education Processes Involved in COPD Patient Engagement Within the Italian Health System

2017 ◽  
pp. 154-181
Author(s):  
Virginia Recchia ◽  
Antonio Dodaro ◽  
Rosita B. Maglie ◽  
Carlo G. Leo
Keyword(s):  
Health System ◽  
Patient Engagement ◽  
World Health ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Common Cause ◽  
The World ◽  
Advance Care ◽  
Health Organization ◽  
Problem Patient

The World Health Organization has estimated that chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death worldwide. Due to the economic and social extent of the problem, patient engagement must be comprised as a new resource for the achievement of higher health outcomes and lower costs. As many key processes involved in the COPD patient engagement consist of communication and education processes, modelling those processes in a whole framework, including actors and content needs, is a requirement. The main scope of this chapter is contributing to design such a framework within the Italian Health System. Final recommendations suggest to create a synergy among patient engagement and a set of legal tools, namely informed consent, integrated care and advance care planning. The synergy is based on the fact that both patient engagement and those legal tools have a common deep root in the universal principle of patient autonomy.

scholarly journals World No Tobacco Day: Tobacco is a Threat to the One Health and Sustainability

2020 ◽  
Vol 25 (11) ◽  
pp. 4347-4350
Author(s):  
Subhash Janardhan Bhore
Keyword(s):  
Tobacco Use ◽  
Tobacco Consumption ◽  
Communicable Diseases ◽  
World Health ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Non Communicable Diseases ◽  
Long Run ◽  
The World ◽  
Health Organization

Abstract On 31st May of every year, in honour of the ‘World No Tobacco Day (WNTD),’ the international community does organise various events and encourages avoiding all forms of Tobacco consumption. To commemorate WNTD-2018, the World Health Organization (WHO) has promoted awareness to highlight the link between Tobacco and cardiovascular disease (CVD). Because, Tobacco use is the second leading cause of CVD, after high blood pressure. In addition to CVD, Tobacco use is also known to cause many non-communicable diseases, including chronic obstructive pulmonary disease (COPD), lung cancer and other complicated disorders caused by smoking. In fact, non-communicable diseases are now emerging as the primary disease burden. Globally, Tobacco use kills about 7 million people each year, and if the trend remains the same, then it will kill more than 8 million people per year by 2030. On the contrary, despite promoting awareness, the Tobacco industry is growing with little or no regulation. However, in the long run, the global community will not be able to afford business as usual as Tobacco has a direct impact on human health, environmental health and sustainable development.

COVID 19: REALS AND CHALLENGES AGAINST DOCTORS

2020 ◽  
Vol 2 (1) ◽  
pp. 65-87
Author(s):  
Zen Ahmad
Keyword(s):  
Virus Disease ◽  
Clinical Manifestations ◽  
World Health ◽  
Unknown Etiology ◽  
Wuhan City ◽  
Traditional Markets ◽  
Pneumonia Case ◽  
The World ◽  
New Type ◽  
Health Organization

Corona Virus Disease (Covid-19) is a contagious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was discovered in December 2019 in China. This disease can cause clinical manifestations in the airway, lung and systemic. The World Health Organization (WHO) representative of China reported a pneumonia case with unknown etiology in Wuhan City, Hubei Province, China on December 31, 2019. The cause was identified as a new type of coronavirus on January 7, 2020 with an estimated source of the virus from traditional markets (seafood market). ) Wuhan city

Sign in / Sign up

Export Citation Format

Share Document